
























































Acta Derm Venereol 2017; 97: 649–650
This is an open access article under the CC BY-NC license. www.medicaljournals.se/acta




Photodynamic therapy (PDT) is a non-invasive treatment 
for several (pre)malignant superficial skin cancers, such 
as superficial basal cell carcinoma (sBCC), Bowen’s 
disease (BD) and actinic keratosis (AK) (1, 2). PDT is 
traditionally known as an in-clinic treatment that can 
be time-consuming for both patients and healthcare 
personnel. Conventional PDT (cPDT) can be painful 
(3). In order to optimize comfort during treatment, new 
photosensitizing agents and light sources have been 
studied over the past decades. 
Moseley et al. (4) reported on the use of a portable low-
irradiance illumination source for sBCC. This ambulatory 
PDT (aPDT) device delivers a standard light dose at low 
irradiance (7 mW/cm2) over a prolonged period of time, 
compared with other devices, such as the Aktilite (80–90 
mW/cm2, Galderma SA, Lausanne, Switzerland) (5). It 
is considered a patient-friendly, out-of-clinic treatment 
with lower pain scores compared with regular PDT (4–6).
This aim of this study was to evaluate retrospectively 
the risk of recurrence in patients treated with aPDT for pri-
mary sBCC, and the effect of tumour size on recurrence. 
MATERIALS AND METHODS
Medical files of patients treated with aPDT between 1 February 
2012 and 31 May 2013 in the Catharina Hospital, the Netherlands, 
were reviewed retrospectively. Inclusion criteria for this study 
were: patients with a histologically confirmed primary sBCC with 
a maximum diameter of 2 cm (due to size limitation of the port-
able PDT device). Exclusion criteria were: patients with genetic 
disorders causing skin cancer and those using immunosuppressive 
medication. The primary outcome measure was 1-year probability 
of remaining tumour-free. Treatment failure was defined as the 
presence of residual or recurrent tumour during follow-up visits. 
Follow-up visits were scheduled according to the local hospital 
protocol 3 and 12 months post-treatment. Secondary outcome 
measures were cumulative probability of recurrence-free survival 
at 6 and 18 months, and incidence of adverse events.
In case of slight hyperkeratosis, lesions were prepared by 
curettage using a wooden spatula to remove scales and crusts, to 
increase penetration of the active agent. Consecutively methyl-
aminolaevulinic acid (Metvix 16%, Galderma SA, Penn Pharma-
ceutical Services, Gwent, UK) was applied to the tumour itself 
and a 5-mm margin of surrounding normal tissue. A transparent 
occlusive bandage (Tegaderm®, 3M Healthcare, Minnesota, USA), 
was applied, after which the portable PDT device (Ambulight®, 
Ambicare Health, Livingston, Scotland, UK) was attached. The 
device remained switched off for 3 h. Subsequently, it switched on 
automatically and remained switched on for another 3 h, thereby 
delivering a total light dose of 75 J/cm2, with 7 mW/cm2 irradiance. 
The distribution of baseline characteristics was described by 
absolute numbers and percentages for categorical variables and 
mean ± standard deviation for age. Kaplan–Meier survival analyses 
were used to assess the cumulative probability of recurrence-free 
survival with 95% confidence intervals (CI) at 6, 12 and 18 months. 
Differences in recurrence-free survival between groups were tested 
for significance using the log-rank test. Follow-up ended at the 
date of a treatment failure or the date of the last follow-up visit. 
A 2-sided p-value ≤ 0.05 was considered to indicate statistical 
significance. Analyses were performed using SPSS version 23.0 
and Stata version 14.0.
RESULTS
During the study period 125 patients with 143 sBCC were 
treated with aPDT. The first diagnosed tumour per patient 
was included for analysis. In case a patient was treated 
for 2 or more primary sBCC on the same day, the largest 
tumour was chosen for analysis. A total of 104 patients 
had a histologically confirmed primary sBCC. Three 
patients were lost to follow-up directly post-treatment, 
because they preferred follow-up elsewhere. Thus, 101 
patients remained for analysis. Baseline characteristics 
are shown in Table SI1. 
Median follow-up time was 13 months (range 2–23 
months) with 59.4% of patients having completed a 
follow-up time of at least 12 months and 27% more than 18 
months. In 11 patients treatment failure was observed ba-
sed on clinical observation, from which 9 occurred within 
12 months. Eight of the clinically suspect recurrences 
were confirmed by histopathological examination, and 3 
tumours were re-treated without histological confirmation. 
A total of 11 recurrences were included in the analysis. 
At 3 months there were no patients with residual 
tumour. At 6, 12 and 18 months the cumulative proba-
bility of recurrence-free survival was 93.6% (95% CI 
86.3–97.1%), 89.9% (95% CI 81.5–94.7%) and 87.6% 
(95% CI 77.4–93.3%). For 74 patients data on tumour 
size was available. These patients were categorized ac-
cording to tumour size: ≤5,  6–10, and > 10 mm. The 
1-year probability of recurrence-free survival was 100% 
for the ≤ 5 mm size group and 92% (95% CI 78.5–97.6%) 
and 72.9% (95% CI 42.6–89.0%) for the 6–10 mm and 
>10 mm groups, respectively, p = 0.014 (Fig. S11). 
Adverse events were reported in 2 patients: one repor-
ted blistering and erosions post-treatment, and the other 
had a bacterial skin infection, which was treated with 
topical antibacterial ointment. 
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The current study suggests that aPDT is an effective 
treatment for primary sBCC, with clearance rates of 
89.9% at 12-month follow-up. It is most effective in 
sBCC smaller than 10 mm. 
The probability of recurrence-free survival following 
aPDT compares favourably with results reported by 
studies on cPDT. Roozeboom et al. (7) found a 1-year 
cumulative probability of 84% (95% CI 78–90%) based 
on pooled estimates of recurrence-free survival in a sys-
tematic review on cPDT treatment of sBCC. In a recent 
prospective randomized controlled trial probability of 
recurrence-free survival of 72.8% (95% CI 66.8–79.4%) 
was reported at 12 months following methyl aminole-
vulinate (MAL)-PDT (8). A possible explanation for 
better results of aPDT might be the different irradiance 
in aPDT. The aPDT device emits red light at low irradi-
ance over a longer period of time. It is hypothesized that 
this low irradiance is more cytotoxic and has a greater 
photobleaching efficiency and therefore could lead to a 
higher efficacy, with lower pain scores (9–11). However, 
the lack of a control group in this study prohibits direct 
comparison with cPDT.
In 2 cases blistering was observed; 1 due to bacterial 
infection. It is possible that the blistering in the second 
patient was also caused by a local skin infection rather 
than by the PDT itself, but this was not explicitly reported 
in the patient file. 
An interesting finding of the current study is that aPDT 
is especially effective in tumours < 10 mm. The decrease 
in treatment success in larger tumours has already been 
reported by Atilli et al. (6) in a small, open, pilot study 
with aPDT. They observed that lesions larger than 1.5 cm 
were more likely to show recurrence. One could argue 
that smaller sBCC, in general, respond better to treatment 
compared with larger ones. However, the literature on 
PDT is not consistent regarding the association between 
tumour size and effectiveness of PDT (12–16). 
An important limitation of this study is its retrospective 
nature. Reports were often brief and post-treatment photo-
graphy was usually not conducted. For this reason, recur-
rences may have been misclassified and adverse events 
may have been under-reported. Currently, aPDT is not 
widely implemented in daily practice in Dutch hospitals. 
A limitation of the device is its inability to treat tu-
mours located on convex or concave areas (e.g. nose, 
fingers) or tumours >2 cm. Since there are viable and 
more cost-effective alternative therapeutic options, such 
as imiquimod or 5-fluourouracil, the position of aPDT 
has to be established. aPDT could be a preferred mode 
of PDT for the working population, for whom in-clinic 
treatment might not be preferable and for patients who 
are not able or willing to apply a cream. Another advan-
tage could be the good tolerance during illumination, in 
contrast to cPDT, in which a burning sensation is more 
often reported (5, 6).
Thus far, there is insufficient evidence to implement 
aPDT on a wide scale and comparison with other existing 
effective treatments in a randomized controlled setting 
is warranted. 
The authors declare no conflicts of interest.
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